Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ATI 502 · A-301, ATI-50002

Other · developed by Aclaris Therapeutics

Phase 2 Most advanced trial (none active)

ACRS Developer

2 Registered trials

What is ATI 502?

ATI 502 is an investigational drug studied in Atopic Dermatitis, Alopecia Areata, Alopecia Universalis.

At a glance

Also known as: A-301, ATI-50002
Drug type: Other
Therapy area: Dermatology
Developer: Aclaris Therapeutics, Inc. (ACRS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: R105E71J13

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03759340	Phase 2	Alopecia Areata	Terminated	ACRS
NCT03585296	Phase 2	Atopic Dermatitis	Completed	ACRS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alopecia AreataAlopecia TotalisAlopecia UniversalisAtopic Dermatitis

More from Aclaris Therapeutics

A-101 FDA approved ATI-045 Phase 2 ATI-1777 Phase 2 ATI-2138 Phase 2 ATI-50002 Phase 2 ATI-501 Phase 2 Zunsemetinib Phase 2

Sources

ClinicalTrials.gov NCT03759340

Updated Oct 3, 2026. Something wrong or missing? Report it on the ACRS page.

Follow ACRS, the company behind ATI 502

See ACRS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ACRS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z